NSCL patients without EGFR mutations and with expression of PD-L1 on ≥50% of tumor cells reacted better to the treatment with pembrolizumab (anti-PD-1 antibody) than to platinum chemotherapy, both in terms of overall survival and side-effect profiles (53). This evidence concerns the gene CD274 and neoplasm.